Anteris Technologies Ltd

Equities

AVR

AU0000088841

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. Other stock markets 02:10:44 2024-04-26 am EDT			5-day change	1st Jan Change
22.75 ^AUD	-1.09%		-1.09%	+18.80%

Apr. 18	Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31	MT
Apr. 10	Anteris Technologies Raises AU$23 Million for DurAVR Study	MT

Anteris Technologies Ltd Auditor Raises 'Going Concern' Doubt

February 27, 2023

Anteris Technologies Ltd filed its Annual on Feb 28, 2023 for the period ending Dec 31, 2022. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Anteris Technologies Ltd

Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31	Apr. 17	MT
Anteris Technologies Raises AU$23 Million for DurAVR Study	Apr. 09	MT
Anteris Declares Upbeat Results from Human Trials of Heart Valve	Mar. 13	MT
Anteris Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Anteris Technologies Completes Enrollment for Heart Valve Device Study	23-10-17	MT
Anteris Technologies Secures AU$1 Million Tax Rebate for 2022	23-10-12	MT
Anteris Technologies Ltd(ASX:AVR) dropped from S&P Global BMI Index	23-09-18	CI
Anteris Technologies Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case	23-08-14	CI
Montefiore Enrolls Patients for US Early Feasibility Study for Anteris Technologies' DurAVR THV	23-08-09	MT
Anteris Technologies Announces First Successful Implantation of Duravr? Thv in A Valve-In-Valve Procedure	23-07-31	CI
Anteris Technologies Implants DurAVR THV in Valve-in-Valve Procedure; Shares Jump 3%	23-07-30	MT
Anteris Technologies Validates Efficacy of Aortic Valve Device	23-06-09	MT
Anteris Technologies Secures US Patent for Transcatheter Heart Valve; Shares Rise 4%	23-05-17	MT
Anteris Technologies, v2vmedtech to Develop Heart Valve Repair Device	23-04-19	MT
Anteris Technologies Ltd acquired 30% stake in v2vmedtech, inc. for $0.37 million.	23-04-18	CI
Australian Shares Rise on Mining, IT Boost Ahead of US Inflation Data	23-04-12	MT
Anteris Technologies Secures US Patent for Heart Valve Product; Shares Rise 3%	23-04-12	MT
US FDA Allows Manufacturing to Start at Anteris Technologies' Expanded Production Facility for DurAVR THV	23-03-26	MT
Anteris Technologies Ltd Announces FDA Allows Manufacturing to Begin At Expanded Facility	23-03-26	CI
Anteris Technologies Ltd(ASX:AVR) added to S&P/ASX All Ordinaries Index	23-03-20	CI
Anteris Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Anteris Technologies Ltd Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Anteris Technologies Raises AU$35 Million for Heart Valve Development	23-02-09	MT
Anteris Technologies Enters Non-Binding Deal for AU$50 Million Facility	23-02-06	MT

Chart Anteris Technologies Ltd

Duration

Period

More charts

Company Profile

Anteris Technologies Ltd is an Australia-based company that is engaged in the research and development (R&D) of its structural heart products. The Company is engaged in the manufacture and sale of ADAPT regenerative tissue products globally. It is focused on developing biomimetic transcatheter aortic valve replacement (TAVR) for the treatment of aortic stenosis. ADAPT is the Companyâs patented anti-calcification tissue technology. Its DurAVR THV is a three dimensional (3D) single piece valve and is a biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The Company also provides ComASUR Delivery System, a balloon expandable system with the ability to rotate valves for predictable alignment with the heartâs native commissure.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-28 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Anteris Technologies Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.75 AUD

Average target price

30 AUD

Spread / Average Target

+31.87%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ANTERIS TECHNOLOGIES LTD	+18.80%	285M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution